Target intelligence / Profile preview

Streptococcus pneumoniae capsular polysaccharide (13 serotypes) (CPS)

Target
CPS
Molecular classification
Polysaccharide, Bacterial surface antigen
01

Overview

The capsular polysaccharide (CPS) of Streptococcus pneumoniae is a complex carbohydrate layer that encapsulates the bacterial cell, serving as its most critical virulence factor. Its primary biological function is to inhibit the host's immune response by preventing opsonization and phagocytosis, thereby allowing the bacteria to survive and disseminate within the host (StatPearls, 2023). There are more than 100 known serotypes of S. pneumoniae, each defined by a unique polysaccharide structure. The 13 serotypes targeted by the PCV13 vaccine (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were historically responsible for the majority of invasive pneumococcal diseases, such as meningitis and bacteremia, as well as community-acquired pneumonia (CDC, 2022). In the context of pharmacology, these polysaccharides are used as vaccine antigens; when conjugated to a carrier protein, they stimulate a T-cell dependent immune response that produces high-affinity antibodies and immunological memory (PubMed, PMID: 25883065). These antibodies bind to the CPS on the surface of live bacteria, facilitating their clearance via the complement system and phagocytic cells.

Other names
Pneumococcal capsular polysaccharideS. pneumoniae CPSPCV13 antigensPneumococcal surface polysaccharidePneumococcal capsule
02

Mechanism of action

Induction of serotype-specific opsonophagocytic antibodies through T-cell dependent (conjugate) or T-cell independent (polysaccharide) immune pathways, leading to bacterial clearance.

03

Biological functions

Immune evasionBacterial virulenceAntiphagocytic activityProtection against environmental stress
04

Disease associations

InfectionPneumoniaMeningitisBacteremiaOtitis mediaSinusitis
05

Safety considerations

Serotype replacement (emergence of non-vaccine serotypes)Hypersensitivity reactionsInjection site reactionsLimited protection against serotypes not included in the formulation
06

Interacting drugs

Pneumococcal 13-valent conjugate vaccine (Prevnar 13)

3 more in the full profile.

07

Biomarkers

Serotype-specific IgG antibody concentrationOpsonophagocytic activity (OPA) titer

Beyond the preview

Go deeper on Streptococcus pneumoniae capsular polysaccharide (13 serotypes) (CPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae capsular polysaccharide (13 serotypes) (CPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call